Home » Stocks » ODT

Odonate Therapeutics, Inc. (ODT)

Stock Price: $3.14 USD 0.08 (2.61%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $3.10 -0.04 (-1.27%) May 7, 7:44 PM
Market Cap 121.22M
Revenue (ttm) n/a
Net Income (ttm) -126.35M
Shares Out 32.86M
EPS (ttm) -3.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.14
Previous Close $3.06
Change ($) 0.08
Change (%) 2.61%
Day's Open 3.06
Day's Range 3.05 - 3.22
Day's Volume 576,645
52-Week Range 3.00 - 46.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

1 day ago - Zacks Investment Research

Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

4 weeks ago - Zacks Investment Research

Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Groupon Inc (NASDAQ: GRPN) shares are trading lower Monday after the company announced a proposed private offering of $200 million of convertible senior notes. Groupon acts as the middleman between cons...

Other stocks mentioned: GRPN
1 month ago - Benzinga

The company's news was so bad that it's going out of business.

1 month ago - The Motley Fool

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut S...

Other stocks mentioned: DYAI, MRKR
1 month ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clin...

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wit...

2 months ago - Business Wire

Odonate has only one drug, an oral version of well-known chemo drugs called taxanes. Its Phase 3 trial was solid, but the market may have misunderstood the data.

3 months ago - Seeking Alpha

Odonate is a small biotech attempting to win approval for Tesetaxel, a chemotherapy treatment indicated for treatment of HER2 negative metastatic breast cancer. The company's share price nose dived from...

3 months ago - Seeking Alpha

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: DNMR, LNG, CQP, FNF, IEP, IQV, SPLP
4 months ago - Benzinga

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, ARVN, BCAB, COUP, EOSE ...
4 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients wi...

4 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wi...

5 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wi...

5 months ago - Business Wire

New York, New York--(Newsfile Corp. - November 16, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 16, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therap...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 16, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dec...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therape...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dec...

5 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 13, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" ...

5 months ago - Newsfile Corp

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and A...

5 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - November 12, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therape...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therape...

5 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 10, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therap...

5 months ago - Newsfile Corp

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) and certain of it...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 30, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dec...

6 months ago - Newsfile Corp

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and A...

6 months ago - PRNewsWire

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wi...

6 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dece...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 15, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dec...

6 months ago - Newsfile Corp

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and A...

6 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Decem...

6 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 2, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between Dece...

7 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 202...

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - September 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NA...

7 months ago - Newsfile Corp

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeuti...

7 months ago - PRNewsWire

SAN DIEGO--(BUSINESS WIRE)---- $ODT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) has filed a class action co...

7 months ago - Business Wire

New York, New York--(Newsfile Corp. - September 18, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...

7 months ago - Newsfile Corp

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odo...

7 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeutics, Inc. (NASD...

7 months ago - Business Wire

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc.

7 months ago - PRNewsWire

A couple of factors appear to be at work after the company announced the pricing of a secondary stock offering.

8 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wi...

8 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients wi...

8 months ago - Business Wire

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Odonate Therapeutics, Inc. (“Odonate” or the “Company”) (NASDAQ: ODT) complied with federal securities laws.

8 months ago - Business Wire

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Odonate Therapeutics, Inc.

8 months ago - PRNewsWire

Odonate Therapeutics (NASDAQ: ODT) shares were trading lower on Monday after the company announced the results from CONTESSA, a Phase 3 study of Tesetaxel, achieved the primary endpoint.

8 months ago - Benzinga

About ODT

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

Industry
Biotechnology
IPO Date
Dec 7, 2017
Stock Exchange
NASDAQ
Ticker Symbol
ODT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ODT stock is "Buy." The 12-month stock price forecast is 4.00, which is an increase of 27.39% from the latest price.

Price Target
$4.00
(27.39% upside)
Analyst Consensus: Buy